Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study.

Objective: To investigate safety and effectiveness of velagliflozin oral solution as sole therapy in naïve and previously insulin-treated diabetic cats.

Animals: 252 client-owned cats receiving ≥ 2 doses of velagliflozin; 214 (85%) naïve diabetics and 38 (15%) insulin-treated diabetics.

Procedures: Prospective, baseline-controlled, open-label clinical field trial.

Relationship between HbA1c, fructosamine and clinical assessment of glycemic control in dogs.

Background: Serum fructosamine is a routine test used for clinical monitoring of diabetes mellitus (DM) but the usefulness of HbA1c for this purpose has not been extensively studied.

Hypothesis: The study aimed to compare the ability of blood HbA1c and serum fructosamine tests to correctly classify DM control determined using a clinically-based assessment.

Animals: 28 client-owned dogs with naturally-occurring diabetes mellitus.

Evaluation of the expression of hexokinase 1, glucokinase, and insulin by canine insulinoma cells maintained in short-term culture.

Objective: To develop a technique for isolation and culture of canine insulinoma cells and assess expression of cellular hexokinases (glucokinase and hexokinase I) and expression and secretion of insulin from these cells in vitro.

Sample: Pancreatic insulinomas and normal pancreatic tissue from 4 and 3 dogs, respectively.

Procedures: Tissues were collected by surgical excision or at necropsy.